Trending at Lumira Ventures

Rare Disease Day 2023

Alyssia Watkin Lumira News, Congruence Therapeutics

Today, February 28th, 2023, is Rare Disease Day. Celebrated internationally, the day is an opportunity to raise awareness and advocate for rare diseases as a human rights priority and work towards a more inclusive society. Over 300 million people globally …

XyloCor Therapeutics Reports Positive Topline Safety and Efficacy Results from Phase 2 EXACT Clinical Trial of XC001 Novel Gene Therapy for Refractory Angina

Alyssia Watkin Portfolio News, Xylocor Therapeutics

No serious adverse events related to drug product were reportedPatients demonstrated improvements in exercise capacity and reductions in episodes of chest painCardiac imaging results provide mechanistic evidence supporting the therapeutic potential of XC001 in cardiovascular disease XyloCor Therapeutics, a clinical-stage …

Cyrano Therapeutics Announces FDA Clearance of IND Application for Phase 2 Clinical Trial of CYR-064 to Treat Post-Viral Smell Loss (Hyposmia)

Alyssia Watkin Portfolio News, Cyrano Therapeutics, Main Page

Currently no FDA-approved therapy for this serious condition Initiation of Phase 2 clinical trial expected to occur in Q2 2023 Cyrano Therapeutics, a biopharmaceutical company developing medicines for patients with hyposmia (smell loss), announced today that the U.S. Food and …

Deka Biosciences, Inc Announces Submission of Investigational New Drug (IND) Application for Lead Oncology Asset, DK210 (EGFR)

Alyssia Watkin Portfolio News, Deka BioSciences

Important Regulatory Milestone Provides Runway to Move DK210 (EGFR) into the Clinical Phase GERMANTOWN, Md., Dec. 27, 2022 /PRNewswire/ — Today, Deka Biosciences, Inc. (Deka), a biotech company focused on developing novel cytokine therapies to treat cancer and inflammatory diseases, announced the submission …

Lumira Ventures Participates In The Closing of PIC Therapeutics $35 Million Series A Financing to Develop Treatments for Drug-Resistant Breast Cancer

Alyssia Watkin Portfolio News, PIC Therapeutics, Main Page

Financing Round Led by OrbiMed with participation from Lumira Ventures, Harrington Discovery Institute and existing investors Advent Life Sciences and Belinda Termeer Therapy development focused on addressing a fundamental mechanism in cancer-driving oncogenes October 19, 2022 – PIC Therapeutics, Inc., …

World Mental Health Day 2022

Alyssia Watkin Lumira News, DAMONA Pharmaceuticals

In 2021, Lumira Ventures and Angelini Pharma launched the Angelini Lumira Biosciences Fund (ALBF) to invest in early-stage companies in Canada and U.S. markets that are developing pharmaceutical therapies for central nervous system disorders (CNS) and rare diseases. Through our …

DAMONA Pharmaceuticals Raises US$5.5 Million Seed Stage Financing to Advance Lead Molecule Development to Treat Cognitive Deficits Associated with Depression and Diseases of Aging

Alyssia Watkin Portfolio News, DAMONA Pharmaceuticals, Main Page

TORONTO, Ontario, September 26, 2022 — DAMONA Pharmaceuticals today announced the closing of a seed stage financing round to support the development of its lead therapeutic for the treatment of cognitive symptoms associated with depression and diseases of aging. The …